HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Clinical, pharmacokinetic, and pharmacodynamic effects of tolcapone withdrawal in levodopa-treated patients with parkinsonism.

Abstract
The effect and clinical significance of tolcapone withdrawal on erythrocyte catechol-O-methyltransferase (COMT) activity, levodopa pharmacokinetics, and levodopa requirements were investigated in 59 patients with fluctuating parkinsonism who were randomized to receive placebo or tolcapone 100 or 200 mg three times daily for 6 weeks. Tolcapone withdrawal caused a transient elevation in COMT activity by 64% in patients receiving 100 mg three times daily and by 128% in those receiving 200 mg three times daily at approximately 1-2 weeks after discontinuation of drug. Thereafter, COMT activity was declining but did not reach baseline values by the 12-week study endpoint. However, this had no effect on plasma levodopa and 3-O-methyldopa (3-OMD) concentrations or on levodopa requirements. During treatment, tolcapone increased "on" time and decreased "off" time; after discontinuation of study medication and levodopa dose adjustment, on and off times were similar to baseline. Withdrawal was generally well tolerated; no patients withdrew from the trial during the posttreatment period, and no serious adverse events were observed. In conclusion, the transient increase in erythrocyte COMT activity observed after discontinuation oftolcapone is not associated with changes in peripheral levodopa metabolism and therefore has no significant clinical consequences in terms of levodopa requirements, clinical symptoms, or adverse events.
AuthorsK M Jorga, T L Davis, M C Kurth, M H Saint-Hilaire, P A LeWitt, B Fotteler, G Zürcher, M Rabbia
JournalClinical neuropharmacology (Clin Neuropharmacol) 2000 Mar-Apr Vol. 23 Issue 2 Pg. 98-105 ISSN: 0362-5664 [Print] UNITED STATES
PMID10803800 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial)
Chemical References
  • Antiparkinson Agents
  • Benzophenones
  • Nitrophenols
  • Tyrosine
  • Levodopa
  • tolcapone
  • Catechol O-Methyltransferase
  • 3-methoxytyrosine
Topics
  • Aged
  • Antiparkinson Agents (adverse effects, blood, therapeutic use)
  • Benzophenones (adverse effects, pharmacokinetics)
  • Catechol O-Methyltransferase (blood)
  • Double-Blind Method
  • Erythrocytes (drug effects, enzymology)
  • Female
  • Humans
  • Levodopa (blood, pharmacokinetics, therapeutic use)
  • Male
  • Nitrophenols
  • Parkinson Disease (drug therapy, enzymology, physiopathology)
  • Substance Withdrawal Syndrome (enzymology, physiopathology)
  • Tyrosine (analogs & derivatives, blood)
  • Up-Regulation (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: